RIVKAL clinical trial for the first-in-human administration of BIM2b in participants with Glioblastoma

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508662-15-00

Acronym

2024-BI-01 (RIVKAL)

Enrollment

Registered

2024-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026